Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vispacabtagene regedleucel
- Development stage
- Phase 1
- Lead developer
- Caribou Biosciences
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Vispacabtagene regedleucel (vispa-cel; formerly CB-010) is an allogeneic anti-CD19 CAR-T cell therapy developed by Caribou Biosciences, Inc. It is engineered using CRISPR genome-editing technology (Cas9 chRDNA) to include a PD-1 knockout, a strategy designed to enhance CAR-T cell activity by preventing premature T-cell exhaustion. This off-the-shelf therapy is being investigated for the treatment of relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
- Other names
- Anti-CD19 CAR-T cell therapy - Caribou BiosciencesAnti-CD-19 CAR-T cell therapy - Caribou BiosciencesAnti-CD 19 CAR-T cell therapy - Caribou BiosciencesAnti-CD19 chimeric antigen receptor T cell therapy - Caribou BiosciencesAnti-CD-19 chimeric antigen receptor T cell therapy - Caribou BiosciencesAnti-CD 19 chimeric antigen receptor T cell therapy - Caribou BiosciencesAnti-CD19-CAR-T cells - Caribou BiosciencesAnti-CD-19-CAR-T cells - Caribou BiosciencesAnti-CD 19-CAR-T cells - Caribou Biosciences
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on vispacabtagene regedleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vispacabtagene regedleucel.